When IL-10 and IL-10/IL-6 were combined for diagnosis, it was found that the sensitivity and specificity could be further improved, reaching 98.9%.[7] It could be used as a biomarker for PCNSL diagnosis. The gene discussed is IL6; the disease is primary central nervous system lymphoma.